Pfizer Inc PFE

$28.40 +0.12 (0.42%)

Valuation

Market cap
161,186,784,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.12
Forward PE
9.35
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
18,555,600
Avg volume
34,774,676
Day's range
$28.28 – $28.50
Shares out
5,699,674,000
Stochastic %K
70%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

karpy Oct 13, 3:15 PM
$PFE Pfizer don’t lose pre-market gains challenge (impossible)
0 replies
Typecheck Oct 13, 2:39 PM
$PFE Okay. It seems like something was happening and then it didn't happen. What is going on?
0 replies
zustrelaax Oct 13, 2:23 PM
$PFE they are trying shake out here , any news this week , $NVAX trying to keep it low
0 replies
pickpro86 Oct 13, 2:22 PM
$PFE $20 sounds much better.
0 replies
PFElinepfrenzy1990 Oct 13, 2:10 PM 0 replies
SellasgpsCurativeBAT11 Oct 13, 12:25 PM
$SLS $JNJ $BMY $MRK $PFE GPS Groundbreaking Curative results will show a huge difference between GPS and BAT. GPS is now approaching transplant survival rates without the huge risks/recovery, means that expansion within AML is all but guaranteed, and expansion into other 20+ cancers that can achieve low disease burden will immediately be followed up on. In this scenario, letting a rival pharma company acquire SLS comes with pretty big risks, so a bidding war becomes likely. I would expect an acquisition to follow fairly quickly in this scenario, probably Results + Deal because Sellas would be very happy to accept the best offer they receive, and whoever the bidder is would want full control over the BLA application and subsequent expansion of further trials ASAP. They would likely be willing to pay the sort of values that get thrown around here based on the expected returns, and Sellas would be very happy to accept an offer! ✌️🙏❤️‍🩹
0 replies
jackofalltrade Oct 13, 11:14 AM
$PFE Top Story Pfizer joins Enodia's bid to develop Sec61 inhibitors as part of $500M deal https://firstwordpharma.com/story/8208096
0 replies
jackofalltrade Oct 13, 11:13 AM
$PFE Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules https://www.enodiatx.com/enodia-therapeutics-announces-research-collaboration-and-license-agreement-with-pfizer-to-develop-sec61-targeting-small-molecules/
0 replies